Novel Antibody Therapies Market: Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Route of Administration (Intratumoral, Intravenous and Intravesical), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Pages
    214

  • View Count
    171

Example Insights

Novel-Antibody-Therapies-Market-Context-thumb Novel-Antibody-Therapies-Market-Development-Pipeline-thumb Novel-Antibody-Therapies-Market-Market-Landscape-thumb
Novel-Antibody-Therapies-Market-Big-Pharma-Players-thumb Novel-Antibody-Therapies-Market-Clinical-Trial-Analysis-thumb Novel-Antibody-Therapies-Market-Publication-Analysis-thumb
Novel-Antibody-Therapies-Market-Patent-Analysis-thumb Novel-Antibody-Therapies-Market-Partnerships-and-Collaborations-thumb Novel-Antibody-Therapies-Market-Likely-Growth-Scenarios-thumb
Novel-Antibody-Therapies-Market-Distribution-by-Type-of-Therapy-thumb    

Overview

Cancer is known to be one of the leading causes of deaths, worldwide. In fact, as per the annual statistics reported by the American Cancer Society (ACS) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although several conventional treatment options, including chemotherapy, radiation therapy and surgery are available to control disease progression and keep malignant cells from spreading throughout the body, these therapies have demonstrated limited efficacy in late-stage cancers. Moreover, traditional chemotherapy and radiation therapy have negative effects on patients' quality of life due to their non-specific and extremely toxic nature. Amidst the recent initiatives undertaken to develop more targeted anti-cancer therapies, novel antibody therapies have emerged to be one of the most suitable option, having demonstrated the capability to selectively target and eliminate tumor cells. The novel antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents. Multiple antibody formats have been engineered to enhance therapeutic efficacy and target proteins that are expressed on the surface of the affected cells. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinguish malignantly transformed cells from regular cells. Various novel antibody therapies such as immuocytokines, immunotoxins, radioimmunoconjugates and intrabodies are being investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents.

Till date, six novel antibody therapies, including Adcetris® (mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, T-cell lymphoma and Hodgkin's disease), Elzonris® (Blastic plasmacytoid dendritic cell neoplasm) Lumoxiti® (Hairy cell leukemia), Pluvicto™ (Prostate cancer), Vicineum™ (Bladder cancer) and Zevalin (Lymphoma) have so far been evaluated and approved for various oncological disorders. In addition, more than 130 novel antibody therapies are being evaluated in various preclinical and clinical stages. Currently, more than 50 companies and academic / research institutes are engaged in the development of novel antibody therapies with enhanced efficacy and several promising leads are anticipated to be commercially launched over the coming decade. Over 4,500 patents related to novel antibodies have been recently filed / granted, demonstrating the innovation and continuous research efforts in this domain. In addition, multiple collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline molecules. Moreover, with the active involvement of big pharma players as well as new entrants, the development pipeline of the novel antibody therapies is likely to expand further. Driven by the growing interest of various stakeholders and encouraging clinical research results, the novel antibody therapies market is anticipated to witness steady growth over the coming years.

Scope of the Report

The ‘Novel Antibody Therapies Market, 2022-2035: Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Route of Administration (Intratumoral, Intravenous and Intravesical), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

  • A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (antibody-directed enzyme prodrug therapy, TCR like antibodies, radioisotope immunoconjugates, immunotoxins, intracellular antibody and immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.
  • A detailed review of the current market landscape of immunocytokines, based on several relevant parameters such as status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, intratumoral and subcutaneous), type of therapy and  target disease indication(s). 
  • A detailed review of the current market landscape of immunotoxins based on several relevant parameters such as status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, intratumoral and intrathecal), and target disease indication(s). 
  • A detailed review of the current market landscape of radioisotope immunoconjugates based on several relevant parameters such as status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotope, route of administration (Intravenous, intracerebroventricular and intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency, mode of administration (injection and infusion) and target disease indication(s). In addition, the chapter includes a list of novel antibody therapies with special designations. Further, the chapter presents a list of players developing novel antibody therapies along with information on their year of establishment, company size and location of headquarters. 
  • Elaborate profiles of the key players engaged in the development of novel antibody therapies (shortlisted on the basis of number of drugs). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
  • A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, which have been published since 2017, based on parameters, such as year of publication, type of article, emerging focus areas, top authors, key journals, most popular publisher and copyright holders.
  • An insightful analysis of the patents filed / granted for novel antibody therapies, between 2017- 2021, based on various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading individual assignees, industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • An analysis of the partnerships that have been established in this domain since 2018, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant type of deals.
  • An analysis of big pharma players engaged in the field of novel antibody therapies, featuring various insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indications, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with novel antibody therapies market in the mid to long term. Based on parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035. Our year wise projections of the current and forecasted opportunity within the novel antibody therapies market have further been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in the development of novel antibody therapies?
  • Which novel antibody therapies are being developed across early and late stages of development?
  • Which geographies are the most active in conducting clinical trials related to novel antibody therapies?
  • What is the focus area of various publications related to the novel antibody therapies?
  • Which are the leading funding institutes / centers supporting the research related to novel antibody therapies?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
  • How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
3.2.1.1. Mechanism of Action of ADEPT
3.2.1.2. Advantages of ADEPT
3.2.1.3. Disadvantages of ADEPT

3.2.2. TCR like Antibodies
3.2.2.1. Mechanism of Action of TCR like Antibodies
3.2.2.2. Advantages of TCR like Antibodies
3.2.2.3. Disadvantages of TCR like Antibodies

3.2.3. Radioisotope Immunoconjugates
3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
3.2.3.2. Advantages of Radioisotope Immunoconjugates
3.2.3.3. Disadvantages of Radioisotope Immunoconjugates

3.2.4. Immunotoxins
3.2.4.1. Mechanism of Action of Immunotoxins
3.2.4.2. Advantages of Immunotoxins
3.2.4.3. Disadvantages of Immunotoxins

3.2.5. Intracellular Antibody
3.2.5.1. Mechanism of Action of Intracellular Antibody
3.2.5.2. Advantages of Intracellular Antibody
3.2.5.3. Disadvantages of Intracellular Antibody

3.2.6. Immunocytokines
3.2.6.1. Mechanism of Action of Immunocytokines
3.2.6.2. Advantages of Immunocytokines
3.2.6.3. Disadvantages of Immunocytokines

3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Mechanism of Action
4.2.3. Analysis by Type of Cytokine
4.2.4. Analysis by Status of Development and Type of Cytokine
4.2.5. Analysis by Type of Antigen / Format
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Mode of Administration
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication(s)

4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.3.1. Analysis by Status of Development
4.3.2. Analysis by Mechanism of Action
4.3.3. Analysis by Type of Toxin
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Mode of Administration
4.3.7. Analysis by Immunotoxin Target
4.3.8. Analysis by Special Drug Designation
4.3.9. Analysis by Route of Administration
4.3.10. Analysis by Target Disease Indication(s)

4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.4.1. Analysis by Status of Development
4.4.2. Analysis by Type of Radioisotopes
4.4.3. Analysis by Status of Development and Type of Radioisotopes
4.4.4. Analysis by Route of Administration
4.4.5. Analysis by Type of Therapy
4.4.6. Analysis by Dosing Frequency
4.4.7. Analysis by Mode of Administration
4.4.8. Analysis by Special Drug Designation
4.4.9. Analysis by Target Disease Indication(s)

4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies)
4.6. Novel Antibody Therapies: List of Developers
4.6.1. Analysis by Type of Player
4.6.2. Analysis by Company Size
4.6.3. Analysis by Year of Establishment
4.6.4. Analysis by Location of Headquarters (Region-wise)
4.6.5. Analysis by Location of Headquarters (Country-wise)
4.6.6. Analysis by Company Size and Region of Headquarters
4.6.7. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. Molecular Templates
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Philogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Roche
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Seagen
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Sesen bio
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Telix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Y-mAbs Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Trial Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Disease Indication(s)
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Type of Treatment
6.2.13. Analysis by Type of Drug
6.2.14. Word Cloud Analysis: Emerging Focus Areas
6.2.15. Analysis by Top Indication(s) and Trial Phase
6.2.16. Analysis by Top Indication(s) and Leading Industry Players
6.2.17. Analysis by Trial Location
6.2.18. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Analysis by Type of Article

7.2.4. Top Authors: Analysis by Number of Publications
7.2.5. Key Journals: Analysis by Number of Publications
7.2.6. Key Journals: Analysis by Impact Factor
7.2.7. Most Popular Publishers: Analysis by Number of Publications
7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications

8. PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
8.2.1. Analysis by Patent Publication Year
8.2.2. Year-wise Trend of Granted Patents
8.2.3. Analysis by Type of Patent
8.2.4. Analysis by Granted Patents and Patent Applications
8.2.5. Analysis by Geography
8.2.6. Analysis by CPC Symbols
8.2.7. Analysis by Type of Applicant
8.2.8. Analysis by Patent Age
8.2.9. Word Cloud Analysis: Emerging Focus Areas
8.2.10. Leading Industry Players: Analysis by Number of Patents
8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
8.2.12. Leading Individual Assignees: Analysis by Number of Patents
8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
8.2.14. Patent Valuation: Analysis Methodology and Parameters
8.2.15. Patent Valuation: Analysis by Relative Valuation

9. PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Year and Type of Partnership
9.1.4. Most Popular Drug: Analysis by Number of Partnerships
9.1.5. Analysis by Types of Novel Antibodies
9.1.6. Analysis by Target Disease Indication(s)
9.1.7. Analysis by Type of Partnership and Target Indication(s)
9.1.8. Analysis by Type of Partner
9.1.9. Most Active Players: Analysis by Number of Partnerships
9.1.10. Most Active Players: Analysis by Type of Partnership
9.1.11. Regional Analysis of Partnerships
9.1.12. Intercontinental and Intracontinental Agreements

10. BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. Scoring Criteria for Key Parameters
10.3. List of Big Pharma Players Focused on Novel Antibody Therapies
10.3.1. Analysis by Supplier Strength
10.3.2. Analysis by Portfolio Strength
10.3.3. Analysis by Portfolio Diversity
10.3.4. Benchmarking: Spider Web Analysis
10.3.5. Benchmarking: Harvey Ball Analysis
10.3.6. Benchmarking: Wind Rose Chart

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.3.1. Adcetris (Seagen)
11.3.1.2. Sales Forecast

11.3.2. Elzonris (Menarini Group)
11.3.2.2. Sales Forecast
11.3.3. Pluvicto (Novartis)
11.3.3.2. Sales Forecast

11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035

11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035

11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035

11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035

11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035

11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.1.1. Target Patient Population
11.9.1.2. Sales Forecast
11.9.1.3. Net Present Value
11.9.1.4. Value Creation Analysis

11.9.2. Fibromun (Philogen)
11.9.2.1. Target Patient Population
11.9.2.2. Sales Forecast
11.9.2.3. Net Present Value
11.9.2.4. Value Creation Analysis

11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.3.1. Target Patient Population
11.9.3.2. Sales Forecast
11.9.3.3. Net Present Value
11.9.3.4. Value Creation Analysis

11.9.4. Nidlegy (Philogen)
11.9.4.1. Target Patient Population
11.9.4.2. Sales Forecast
11.9.4.3. Net Present Value
11.9.4.4. Value Creation Analysis

11.9.5. T-Guard (Xenikos)
11.9.5.1. Target Patient Population
11.9.5.2. Sales Forecast
11.9.5.3. Net Present Value
11.9.5.4. Value Creation Analysis

11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.6.1. Target Patient Population
11.9.6.2. Sales Forecast
11.9.6.3. Net Present Value
11.9.6.4. Value Creation Analysis

11.9.7. Vicinium (Sesen Bio)
11.9.7.1. Target Patient Population
11.9.7.2. Sales Forecast
11.9.7.3. Net Present Value
11.9.7.4. Value Creation Analysis

12. APPENDIX 1: TABULATED DATA

13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Novel Antibody Therapies
Figure 3.2 Mechanism of Action of ADEPT
Figure 3.3 Mechanism of Action of TCR like Antibodies
Figure 3.4 Mechanism of Action of Radioisotope Immunoconjugates
Figure 3.5 Mechanism of Action of Immunotoxins
Figure 3.6 Mechanism of Action of Intracellular Antibody
Figure 3.7 Mechanism of Action of Immunocytokines
Figure 3.8 Therapeutic Antibodies: Development Approaches
Figure 4.1 Immunocytokines: Distribution by Status of Development
Figure 4.2 Immunocytokines: Distribution by Mechanism of Action
Figure 4.3 Immunocytokines: Distribution by Type of Cytokine
Figure 4.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Figure 4.5 Immunocytokines: Distribution by Type of Antigen / Format
Figure 4.6 Immunocytokines: Distribution by Dosing Frequency
Figure 4.7 Immunocytokines: Distribution by Type of Therapy
Figure 4.8 Immunocytokines: Distribution by Mode of Administration
Figure 4.9 Immunocytokines: Distribution by Route of Administration
Figure 4.10 Immunocytokines: Distribution by Target Disease Indication(s)
Figure 4.11 Immunotoxins: Distribution by Status of Development
Figure 4.12 Immunotoxins: Distribution by Mechanism of Action
Figure 4.13 Immunotoxins: Distribution by Type of Toxin
Figure 4.14 Immunotoxins: Distribution by Dosing Frequency
Figure 4.15 Immunotoxins: Distribution by Type of Therapy
Figure 4.16 Immunotoxins: Distribution by Mode of Administration
Figure 4.17 Immunotoxins: Distribution by Immunotoxin Target
Figure 4.18 Immunotoxins: Distribution by Special Drug Designation
Figure 4.19 Immunotoxins: Distribution by Route of Administration
Figure 4.20 Immunotoxins: Distribution by Target Disease Indication(s)
Figure 4.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Figure 4.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
Figure 4.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
Figure 4.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Figure 4.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Figure 4.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Figure 4.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Figure 4.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Figure 4.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Figure 4.30 Novel Antibody Therapies Developers: Distribution by Type of Player
Figure 4.31 Novel Antibody Therapies Developers: Distribution by Company Size
Figure 4.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Figure 4.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Figure 4.36 Leading Players: Distribution by Number of Therapeutics
Figure 5.1 Molecular Templates: Financial Information (2016-2021)
Figure 5.2 Philogen: Financial Information (2017-2021)
Figure 5.3 Roche: Financial Information (2016-2021)
Figure 5.4 Seagen: Financial Information (2016-2021)
Figure 5.5 Sesen bio: Financial Information (2020-2021)
Figure 5.6 Telix Pharmaceuticals: Financial Information (2018-2021)
Figure 5.7 Y-mAbs Therapeutics: Financial Information (2020-2021)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2001- April 2022)
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.8 Clinical Trial Analysis: Distribution by Disease Indication(s)
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.13 Clinical Trial Analysis: Distribution by Type of Drug
Figure 6.14 Word Cloud Analysis: Emerging Focus Areas
Figure 6.15 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Figure 6.16 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Figure 6.17 Clinical Trial Analysis: Distribution by Trial Location
Figure 6.18 Clinical Trial Analysis: Distribution by Geography and Trial Status
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
Figure 7.3 Publication Analysis: Distribution by Type of Article
Figure 7.3 Top Authors: Distribution by Number of Publications
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Most Popular Publishers: Distribution by Number of Publications
Figure 7.7 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 8.1 Patent Analysis: Distribution by Patent Publication Year
Figure 8.2 Patent Analysis: Year-wise Distribution of Granted Patents
Figure 8.3 Patent Analysis: Distribution by Type of Patent
Figure 8.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
Figure 8.5 Patent Analysis: Distribution by Geography
Figure 8.6 Patent Analysis: Distribution by CPC Symbols
Figure 8.7 Patent Analysis: Distribution by Type of Applicant
Figure 8.8 Patent Analysis: Distribution of Patents by Age
Figure 8.9 Word Cloud Analysis: Emerging Focus Areas
Figure 8.10 Leading Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.14 Patent Valuation: Distribution by Relative Valuation
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Most Popular Drug: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
Figure 9.8 Most Active Players: Distribution by Number of Partnership
Figure 9.9 Partnerships and Collaborations: Distribution by Most Active Player and Type of Partnership
Figure 9.10 Regional Distribution of Partnerships
Figure 9.11 Intercontinental and Intracontinental Agreements
Figure 10.1 Distribution by Supplier Strength
Figure 10.2 Distribution by Portfolio Strength
Figure 10.3 Distribution by Portfolio Diversity
Figure 10.4 Benchmarking: Spider Web Analysis
Figure 10.5 Benchmarking: Harvey Ball Analysis
Figure 10.6 Benchmarking: Wind Rose Chart
Figure 11.1 Global Novel Antibody Therapies Market, 2022-2035 (USD Billion)
Figure 11.2 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.3 Elzonris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.4 Pluvicto Sales Forecast, 2022-2035 (USD Billion)
Figure 11.5 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Figure 11.6 Novel Antibody Therapies Market for Immunocytokines, 2022-2035 (USD Billion)
Figure 11.7 Novel Antibody Therapies Market for Immunotoxin, 2022-2035 (USD Billion)
Figure 11.8 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2022-2035 (USD Billion)
Figure 11.9 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Figure 11.10 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2022-2035 (USD Billion)
Figure 11.11 Novel Antibody Therapies Market for Bladder Cancer, 2022-2035 (USD Billion)
Figure 11.12 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2022-2035 (USD Billion)
Figure 11.13 Novel Antibody Therapies Market for Graft-versus-host disease, 2022-2035 (USD Billion)
Figure 11.14 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion)
Figure 11.15 Novel Antibody Therapies Market for Prostate Cancer, 2022-2035 (USD Billion)
Figure 11.16 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2022-2035 (USD Billion)
Figure 11.17 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Figure 11.18 Novel Antibody Therapies Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 11.19 Novel Antibody Therapies Market for Monotherapy, 2022-2035 (USD Billion)
Figure 11.20 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Figure 11.21 Novel Antibody Therapies Market for Intratumoral Drugs, 2022-2035 (USD Billion)
Figure 11.22 Novel Antibody Therapies Market for Intravenous Drugs, 2022-2035 (USD Billion)
Figure 11.23 Novel Antibody Therapies Market for Intravesical Drugs, 2022-2035 (USD Billion)
Figure 11.24 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Figure 11.25 Novel Antibody Therapies Market in North America, 2022-2035 (USD Billion)
Figure 11.26 Novel Antibody Therapies Market in Europe, 2022-2035 (USD Billion)
Figure 11.27 Novel Antibody Therapies Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 11.28 Adcetris: Target Patient Population
Figure 11.29 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.30 Fibromun: Target Patient Population
Figure 11.31 Fibromun Sales Forecast, 2022-2035 (USD Billion)
Figure 11.32 Iomab-B: Target Patient Population
Figure 11.33 Iomab-B Sales Forecast, 2022-2035 (USD Billion)
Figure 11.34 Nidlegy: Target Patient Population
Figure 11.35 Nidlegy Sales Forecast, 2022-2035 (USD Billion)
Figure 11.36 T-Guard: Target Patient Population
Figure 11.37 T-Guard Sales Forecast, 2022-2035 (USD Billion)
Figure 11.38 TLX 591: Target Patient Population
Figure 11.39 TLX 591 Sales Forecast, 2022-2035 (USD Billion)
Figure 11.40 Vicinium: Target Patient Population
Figure 11.41 Vicinium Forecast, 2022-2035 (USD Billion)

List Of Tables

Table 4.1 Novel Antibody Therapies (Immunocytokines): Development Pipeline
Table 4.2 Novel Antibody Therapies (Immunotoxins): Development Pipeline
Table 4.3 Novel Antibody Therapies (Radioisotope immunoconjugates): Development Pipeline
Table 4.4 Novel Antibody Therapies (Other Antibodies): Development Pipeline
Table 4.5 Novel Antibody Therapies: List of Developers
Table 5.1 Actinium Pharmaceuticals: Product Portfolio
Table 5.2 Recent Developments and Future Outlook
Table 5.3 Molecular Templates: Product Portfolio
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Philogen: Product Portfolio
Table 5.6 Recent Developments and Future Outlook
Table 5.7 Roche: Product Portfolio
Table 5.8 Recent Developments and Future Outlook
Table 5.9 Seagen: Product Portfolio
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Sesen bio: Product Portfolio
Table 5.12 Recent Developments and Future Outlook
Table 5.13 Telix Pharmaceuticals: Product Portfolio
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Y-mAbs Therapeutics: Product Portfolio
Table 5.16 Recent Developments and Future Outlook
Table 6.1 List of Clinical Trials focused on Novel Antibody Therapies (Pre 2016-2022)
Table 7.1 List of Publications focused on Novel Antibody Therapies (2017-2022)
Table 8.1 List of Patents focused on Novel Antibody Therapies (2017-2022)
Table 9.1 Novel Antibody Therapies: List of Partnerships and Collaborations (2014-2021)
Table 10.1 List of Big Pharma Player Focused on Novel Antibody Therapies
Table 11.1 Adcetris: Target Patient Population
Table 11.2 Adcetris: Net Present Value (USD Billion)
Table 11.3 Elzonris: Target Patient Population
Table 11.4 Elzonris: Net Present Value (USD Billion)
Table 11.5 Fibromun: Target Patient Population
Table 11.6 Fibromun: Net Present Value (USD Billion)
Table 11.7 Iomab-B: Target Patient Population
Table 11.8 Iomab-B: Net Present Value (USD Billion)
Table 11.9 Nidlegy: Target Patient Population
Table 11.10 Nidlegy: Net Present Value (USD Billion)
Table 11.11 Pluvicto: Target Patient Population
Table 11.12 Pluvicto: Net Present Value (USD Billion)
Table 11.13 T-Guard: Target Patient Population
Table 11.14 T-Guard: Net Present Value (USD Billion)
Table 11.15 TLX 591: Target Patient Population
Table 11.16 TLX 591: Net Present Value (USD Billion)
Table 11.17 Vicinium: Target Patient Population
Table 11.18 Vicinium: Net Present Value (USD Billion)
Table 12.1 Immunocytokines: Distribution by Status of Development
Table 12.2 Immunocytokines: Distribution by Mechanism of Action
Table 12.3 Immunocytokines: Distribution by Type of Cytokine
Table 12.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Table 12.5 Immunocytokines: Distribution by Type of Antigen / Format
Table 12.6 Immunocytokines: Distribution by Dosing Frequency
Table 12.7 Immunocytokines: Distribution by Type of Therapy
Table 12.8 Immunocytokines: Distribution by Mode of Administration
Table 12.9 Immunocytokines: Distribution by Route of Administration
Table 12.10 Immunocytokines: Distribution by Target Disease Indication(s)
Table 12.11 Immunotoxins: Distribution by Status of Development
Table 12.12 Immunotoxins: Distribution by Mechanism of Action
Table 12.13 Immunotoxins: Distribution by Type of Toxin
Table 12.14 Immunotoxins: Distribution by Dosing Frequency
Table 12.15 Immunotoxins: Distribution by Type of Therapy
Table 12.16 Immunotoxins: Distribution by Mode of Administration
Table 12.17 Immunotoxins: Distribution by Immunotoxin Target
Table 12.18 Immunotoxins: Distribution by Special Drug Designation
Table 12.19 Immunotoxins: Distribution by Route of Administration
Table 12.20 Immunotoxins: Distribution by Target Disease Indication(s)
Table 12.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Table 12.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
Table 12.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
Table 12.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Table 12.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Table 12.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Table 12.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Table 12.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Table 12.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Table 12.30 Novel Antibody Therapies Developers: Distribution by Type of Players
Table 12.31 Novel Antibody Therapies Developers: Distribution by Company Size
Table 12.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Table 12.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Table 12.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Table 12.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Table 12.36 Leading Players: Distribution by Number of Therapeutics
Table 12.37 Molecular Templates: Financial Information
Table 12.38 Philogen: Financial Information
Table 12.39 Roche: Financial Information
Table 12.40 Seagen: Financial Information
Table 12.41 Sesen bio: Financial Information
Table 12.42 Telix Pharmaceuticals: Financial Information
Table 12.43 Y-mAbs Therapeutics: Financial Information
Table 12.44 Clinical Trial Analysis: Distribution by Trial Status
Table 12.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Table 12.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2016- April 2022)
Table 12.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.48 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 12.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 12.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.51 Clinical Trial Analysis: Distribution by Disease Indication(s)
Table 12.52 Clinical Trial Analysis: Distribution by Study Design
Table 12.53 Most Active Industry Players: Distribution by Number of Trials
Table 12.54 Most Active Non-Industry Players: Distribution by Number of Trials
Table 12.55 Clinical Trial Analysis: Distribution by Type of Treatment
Table 12.56 Clinical Trial Analysis: Distribution by Type of Drug
Table 12.57 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Table 12.58 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Table 12.59 Clinical Trial Analysis: Distribution by Trial Location
Table 12.60 Clinical Trial Analysis: Distribution by Geography and Trial Status
Table 12.61 Publication Analysis: Distribution by Year of Publication
Table 12.62 Publication Analysis: Distribution by Type of Article
Table 12.63 Top Authors: Distribution by Number of Publications
Table 12.64 Key Journals: Distribution by Number of Publications
Table 12.65 Key Journals: Distribution by Impact Factor
Table 12.66 Most Popular Publishers: Distribution by Number of Publications
Table 12.67 Most Popular Copyright Holders: Distribution by Number of Publications
Table 12.68 Patent Analysis: Distribution by Patent Publication Year
Table 12.69 Patent Analysis: Year-wise Distribution of Granted Patents
Table 12.70 Patent Analysis: Distribution by Type of Patent
Table 12.71 Patent Analysis: Distribution by Granted Patents and Patent Applications
Table 12.72 Patent Analysis: Distribution by Geography
Table 12.73 Patent Analysis: Distribution by CPC Symbols
Table 12.74 Patent Analysis: Distribution by Type of Applicant
Table 12.75 Patent Analysis: Distribution by Patent Age
Table 12.76 Leading Industry Players: Distribution by Number of Patents
Table 12.77 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.78 Leading Individual Assignees: Distribution by Number of Patents
Table 12.79 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 12.80 Patent Valuation: Distribution by Relative Valuation
Table 12.81 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.84 Most Popular Drug: Distribution by Number of Partnerships
Table 12.85 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Table 12.86 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 12.87 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
Table 12.88 Most Active Players: Distribution by Number of Partnership
Table 12.89 Partnerships and Collaborations: Distribution by Most Active Partner and Type of Partnership
Table 12.90 Regional Distribution of Partnerships
Table 12.91 Intercontinental and Intracontinental Agreements
Table 12.92 Global Novel Antibody Therapies Market, 2022 and 2035 (USD Billion)
Table 12.93 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.94 Elzonris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.95 Pluvicto Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.96 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Table 12.97 Novel Antibody Therapies Market for Immunocytokines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.98 Novel Antibody Therapies Market for Immunotoxin, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.99 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.100 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Table 12.101 Novel Antibody Therapies Market for Acute Myeloid Leukemia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.102 Novel Antibody Therapies Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.103 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.104 Novel Antibody Therapies Market for Graft-versus-host disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.105 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.106 Novel Antibody Therapies Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.107 Novel Antibody Therapies Market for Soft-tissue sarcoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.108 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Table 12.109 Novel Antibody Therapies Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.110 Novel Antibody Therapies Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion))
Table 12.111 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Table 12.112 Novel Antibody Therapies Market for Intratumoral Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.113 Novel Antibody Therapies Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.114 Novel Antibody Therapies Market for Intravesical Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.115 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Table 12.116 Novel Antibody Therapies Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.117 Novel Antibody Therapies Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.118 Novel Antibody Therapies Market in Asia Pacific Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.119 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.120 Fibromun Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.121 Iomab-B Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.122 Nidlegy Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.123 T-Guard Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.124 TLX 591 Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.125 Vicinium sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3P Biopharmaceuticals
  2. Aachen University Hospital
  3. Actinium Pharmaceuticals
  4. Active Biotech
  5. Adium
  6. Alkido Pharma
  7. Ajinomoto Bio-Pharma
  8. Albert Einstein College of Medicine
  9. Alopexx Oncology
  10. Angimmune
  11. APEIRON Biologics
  12. Astellas Pharma
  13. AstraZeneca
  14. atbtherapeutics
  15. Atonco
  16. AVEO Oncology
  17. Avid Bioservices
  18. Bayer
  19. Beijing Shenogen Pharmaceutical 
  20. Biogen
  21. Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
  22. Bright Peak Therapeutics
  23. Bristol Myers Squibb
  24. Cardinal Health
  25. City of Hope Medical Center
  26. Dana-Farber Cancer Institute
  27. Duke University
  28. Eastern Hepatobiliary Surgery Hospital (EHBH)
  29. Eckert & Ziegler
  30. Eczac?ba??-Monrol
  31. Eli Lilly
  32. EMD Serono
  33. EpicentRx
  34. Eureka Therapeutics
  35. Evergreen Theragnostics
  36. Fred Hutchinson Cancer Research Center
  37. FUJIFILM Pharmaceuticals U.S.A.
  38. Fusion Pharmaceuticals
  39. Genentech
  40. GenesisCare
  41. Genmab
  42. Geno Pharmaceuticals
  43. Gilead Sciences
  44. Global Medical Solutions
  45. Grand Pharmaceutical
  46. Great Ormond Street Hospital for Children NHS Foundation Trust
  47. GT Biopharma
  48. Heidelberg University Hospital
  49. Hikma Pharmaceuticals
  50. iBio
  51. Idec Pharmaceuticals (merged with Biogen)
  52. Immatics Biotechnologies
  53. Immedica Pharma
  54. Immunomedics
  55. Innate Pharma
  56. InterX
  57. IONETIX
  58. Iovance Biotherapeutics
  59. ITM Isotope Technologies Munich
  60. Janssen Research & Development
  61. Kanaph Therapeutics
  62. Kettering Health
  63. King's College London
  64. LifeArc
  65. Livzon MABPharm
  66. Ludwig Institute for Cancer Research
  67. M.D. Anderson Cancer Center
  68. Massachusetts General Hospital
  69. Massachusetts Institute of Technology (MIT)
  70. McMaster University
  71. Memorial Sloan Kettering Cancer Center
  72. Menarini Group
  73. Merck
  74. Molecular Templates
  75. Nammi Therapeutics
  76. NanoMab
  77. National Cancer Institute (NCI)
  78. National Institute of Allergy and Infectious Diseases (NIAID)
  79. National Institute of Health and Medical Research (INSERM)
  80. National Institutes of Health Clinical Center (NIHCC)
  81. NIOWAVE
  82. Nippon Shinyaku
  83. Nordic Nanovector
  84. NorthStar Medical Radioisotopes
  85. Novartis
  86. OncoBeta
  87. OncoTherapy Science
  88. Orano Med
  89. Oslo University Hospital
  90. Pfizer
  91. Philogen
  92. POINT Biopharma Global
  93. Precirix
  94. ProMIS Neurosciences
  95. Qilu Pharmaceutical
  96. Radiopharm Theranostics
  97. Recepta Biopharma
  98. Roche 
  99. Romagnolo Institute for the Study of Tumors "Dino Amadori"
  100. Sanofi
  101. SciClone Pharmaceuticals
  102. Scripps Research
  103. Seagen
  104. Sesen Bio
  105. SHINE Technologies
  106. Stemline Therapeutics
  107. Swixx BioPharma
  108. Takeda
  109. Telix Pharmaceuticals
  110. TRIUMF
  111. University of California
  112. University of Pennsylvania
  113. University of Southampton
  114. University of Texas
  115. USHEALTH
  116. Vanderbilt University
  117. Vertex Pharmaceuticals
  118. Vybion
  119. Xenikos
  120. Y-mAbs Therapeutics

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com